Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31567045 | 0.81 | TNF (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL21996002 | 0.81 | TNF (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL4812657 | 0.79 | HTR2A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL29616362 | 0.77 | TNF (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL3087235 | 0.77 | TNF (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL29449513 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL2329832 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL9293416 | 0.76 | CYP3A4 (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL112218 | 0.75 | HDAC4 (0.36) | — | |
| SCHEMBL584965 | 0.75 | KDM1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | disclosed |
| WO-2008009908-A1 | PYRIDO [2, 3-B] PYRAZINE DERIVATIVES USEFUL AS HERBICIDAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007136572-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136573-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265332-A1 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME LLC | 2007-11-15 | — | — | US | disclosed |
| WO-2006076317-A9 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1836202-A2 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | Acadia Pharmaceuticals Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007092400-A1 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060173037-A1 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076317-A2 | AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060160845-A1 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265332-A1 | Antidiabetic bicyclic compounds | GPR119, GPR65, FFAR4 | HTR2A 393/4885HTR2C 695/4885HTR2B 1035/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | HTR2A 857/4885HTR2C 1466/4885HTR2B 1012/4885 |
| US-20060173037-A1 | Aminophenyl derivatives as selective androgen receptor modulators | AR, NR5A1, ESRRA | HTR2A 224/4885HTR2C 179/4885HTR2B 287/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | HTR2A 4338/4885HTR2C 4328/4885HTR2B 4763/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | HTR2A 3912/4885HTR2C 3081/4885HTR2B 3952/4885 |
| US-20060160845-A1 | Aminophenyl derivatives as selective androgen receptor modulators | AR, NR5A1, ESRRA | HTR2A 224/4885HTR2C 179/4885HTR2B 287/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | HTR2A 4338/4885HTR2C 4328/4885HTR2B 4763/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | HTR2A 857/4885HTR2C 1466/4885HTR2B 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.